Inovio Pharma (INO) Misses Q4 EPS by 14c, Revenues Miss

Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.38), $0.14 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $279 thousand versus the consensus estimate of $2.32 million.

Dr. J. Joseph Kim, INOVIO's President & CEO, said, "The company remains well-positioned for 2020 to be a transformational year for INOVIO. Following our very encouraging, albeit early, positive data for INO-5401 in our GBM study, we look forward to presenting 12-month overall survival data next quarter. We also continue to expand our capabilities in treating HPV-associated diseases, with IND acceptance from the FDA for a Phase 2 trial evaluating INO-3107 for the rare, orphan disease RRP. We also look forward to sharing interim efficacy and safety data from our Phase 2 study in HPV-associated vulvar HSIL and anal HSIL at ASCCP later this month."

"The evolving situation following the outbreak of COVID-19 has allowed us to further showcase INOVIO's technology capabilities and versatility in fighting emerging infectious diseases. We are very grateful for both the financial and moral support from CEPI to take steps toward tackling this global pandemic. Our DNA medicine platform has been selected among a small group of important vaccine technologies for rapidly impacting emerging infectious diseases outbreaks such as COVID-19, having already advanced INO-4700, our vaccine candidate against MERS-CoV, another coronavirus, to a Phase 1/2a clinical trial. We look forward to sharing more on INO-4800\'s development along with our broader pipeline initiatives and achievements in the future."

For earnings history and earnings-related data on Inovio Pharma (INO) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Ennis (EBF) Reports In-Line Q1 EPS
• Johnson Outdoors names Asad Rahman as new CFO effective June 30